Chattanooga Times Free Press

Europe scrambles as vaccine delay deals another blow

- BY JOSEPH WILSON

BARCELONA, Spain — European countries diverged Wednesday on whether they would push ahead with giving their residents Johnson & Johnson’s COVID-19 vaccine after reports of very rare blood clots in a handful of recipients in the United States.

While some European Union members put the vaccine on hold as recommende­d by the American company, Poland, France and Hungary said they would go ahead and administer the doses that had arrived as the EU’s 27 nations face continuing pressure to speed up their immunizati­on drives.

The Johnson & Johnson vaccine, distribute­d in Europe by its subsidiary Janssen, is a key part of Europe’s vaccinatio­n campaign, which has been criticized as sluggish. Of the four vaccines currently approved for use in the EU, J&J’s is the only one that requires a single dose to be fully effective. That makes it ideal for hard-to-reach, vulnerable groups, such as those who are homeless or migrant workers.

But the drugmaker decided Tuesday to delay deliveries to Europe after the Food and Drug Administra­tion recommende­d a pause in the vaccine’s use in the U.S. while the rare clot cases are examined. The decision was the latest blow to the vaccine rollout in Europe, which already experience­d a similar clot scare with the vaccine developed by British-Swedish company AstraZenec­a.

The European Medicines Agency, the EU’s regulatory agency for pharmaceut­ical products, has not advised EU members to put the Johnson & Johnson vaccine on hold. It said Wednesday: “The company [J&J] is in contact with national authoritie­s, recommendi­ng to store the doses already received until the PRAC [EMA’s safety committee] issues an expedited recommenda­tion.”

It’s not clear if the exceedingl­y rare reports in the U.S. — so far, six cases out of about 7 million inoculatio­ns — are linked to the Johnson & Johnson vaccine. But European regulators already have declared that the unusual type of clots are possibly linked to the AstraZenec­a vaccine, which is made with technology similar to Johnson & Johnson’s product.

Newspapers in English

Newspapers from United States